SUPN

Supernus Pharmaceuticals, Inc. NGM · SUPN

$46.94 -0.93 (-1.94%)

Neutral · -0.22σ Grade C

+ Compare Open in Sniper

Valuation

Market cap $2.7B

P/E (ttm) —

Forward P/E 10.8

Beta (5y) 0.54

Shares out 58.0M

Div yield —

Profitability & returns

ROE -2.8%

Net margin -3.7%

FCF margin 17.1%

Debt / equity 0.04

Trading information

Last price $46.94

Day range $46.81 – $48.12

52-wk range $42.45 – $59.68

Avg volume 0.8M

RSI (2) 20.5

Trend zone Neutral

52-week range · today's price

$42.45$59.68

Company

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Exchange NGM

Next earnings 2026-08-04

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (P…